Valrocemide (Teva/Acorda).
Valrocemide is an anticonvulsant agent under development by Teva and Acorda as a potential therapeutic for the treatment of epilepsy. In October 2003, a phase II trial using valrocemide as an adjunct therapy in refractory epilepsy patients had been completed and phase III trials were being planned. Valrocemide was also being investigated for potential utility in the treatment of bipolar disorder and neuropathic pain.
Hovinga
Collin A
CA
Miami Children's Hospital, Research Institute/Brain Institute, 3100 SW 62nd Ave, Miami FL 33155, USA. cahovinga@aol.com
D000544:Alzheimer Disease / Q000188:drug therapy*; D000818:Animals; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D005998:Glycine / Q000031:analogs & derivatives / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D010330:Patents as Topic; D013329:Structure-Activity Relationship
C108894:TV 1901; D005998:Glycine